Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4131 Comments
1854 Likes
1
Clarixa
Daily Reader
2 hours ago
This feels like I should not ignore this.
👍 130
Reply
2
Vinod
Legendary User
5 hours ago
As a working mom, timing like this really matters… missed it.
👍 141
Reply
3
Alai
Daily Reader
1 day ago
Comprehensive US stock balance sheet stress testing and liquidity analysis for downside risk assessment. We model different scenarios to understand how companies would perform under adverse conditions.
👍 79
Reply
4
Shallen
New Visitor
1 day ago
A real star in action. ✨
👍 219
Reply
5
Asil
Senior Contributor
2 days ago
Who else is trying to figure this out step by step?
👍 173
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.